DeepMed Research

UNIVERSITY OF SYDNEY

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Established: 1850-01-01

Employees: -

Market Cap: -

Website: https://www.sydney.edu.au/

Clinical Trials

Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)

Phase 4

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: Aflibercept
Procedure: Targeted laser therapy

First Posted Date: 2015-05-04

Last Posted Date: 2022-05-31

Lead Sponsor: University of Sydney

Target Recruit Count: 48

Registration Number: NCT02432547

Locations: 🇦🇺
Centre for Eye Research Australia, Melbourne, Victoria, Australia
🇦🇺
Save Sight Institute, Sydney, New South Wales, Australia

Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring

Phase 2

Conditions: Prostate Cancer

Interventions: Radiation: Multi-fraction SABR

First Posted Date: 2015-03-24

Last Posted Date: 2017-06-22

Lead Sponsor: University of Sydney

Target Recruit Count: 48

Registration Number: NCT02397317

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
🇦🇺
Liverpool Cancer Therapy Centre, Sydney, New South Wales, Australia

and more 2 locations

CPAP in Preeclampsia

Not Applicable

Terminated

Conditions: Preeclampsia
Hypertension

Interventions: Device: Continuous Positive Airway Pressure Ventilation (CPAP)

First Posted Date: 2014-12-01

Last Posted Date: 2018-05-03

Lead Sponsor: University of Sydney

Target Recruit Count: 5

Registration Number: NCT02303834

Locations: 🇦🇺
Royal Hospital for Women, Sydney, New South Wales, Australia
🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation

Phase 1

Conditions: Acute Myeloid Leukaemia

Interventions: Biological: Partially HLA-matched unrelated donor cells

First Posted Date: 2014-07-15

Last Posted Date: 2015-11-01

Lead Sponsor: University of Sydney

Target Recruit Count: 12

Registration Number: NCT02189824

Locations: 🇦🇺
Westmead Hospital Department of Haematology, Westmead, Sydney, New South Wales, Australia

Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema

Not Applicable

Completed

Conditions: Diabetic Macular Oedema

Interventions: Device: Ellex Integre NIR laser

First Posted Date: 2014-07-03

Last Posted Date: 2020-02-07

Lead Sponsor: University of Sydney

Target Recruit Count: 21

Registration Number: NCT02181400

Locations: 🇦🇺
Sydney Eye Hospital, Sydney, New South Wales, Australia

Sub-Study of the PREVIEW Study Australia

Not Applicable

Conditions: Obesity
Pre-diabetes

Interventions: Behavioral: Low calorie diet administered from 0 to 2 months
Behavioral: Moderate Protein / High Glycaemic Index
Behavioral: High Protein / Low Glycaemic Index

First Posted Date: 2014-01-08

Last Posted Date: 2021-04-30

Lead Sponsor: University of Sydney

Target Recruit Count: 292

Registration Number: NCT02030249

Locations: 🇦🇺
The University of Sydney, Camperdown, New South Wales, Australia
🇦🇺
Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia
🇦🇺
Prince of Wales Hospital, Randwick, Sydney, New South Wales, Australia

Using Implementation Intentions to Increase Safe Sex Practices in MSM

Not Applicable

Conditions: HIV
Sex

Interventions: Behavioral: Planning tasks

First Posted Date: 2013-08-20

Last Posted Date: 2013-08-20

Lead Sponsor: University of Sydney

Target Recruit Count: 180

Registration Number: NCT01926418

Locations: 🇦🇺
The Albion Center, Sydney, New South Wales, Australia

99m-Technetium- Glucosamine in Arthritis

Conditions: Rheumatoid Arthritis
Ankylosing Spondylitis

First Posted Date: 2013-02-11

Last Posted Date: 2016-10-31

Lead Sponsor: University of Sydney

Registration Number: NCT01789151

Locations: 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia

Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Phase 2

Completed

Conditions: Diabetes
Diabetic Macular Oedema
Diabetic Macular Edema
Diabetic Retinopathy

Interventions: Drug: Ozurdex (dexamethasone)
Drug: Avastin (Bevacizumab)

First Posted Date: 2013-02-08

Last Posted Date: 2018-11-13

Lead Sponsor: University of Sydney

Target Recruit Count: 19

Registration Number: NCT01787669

Locations: 🇦🇺
Centre for Eye Research Australia (Royal Victorian Eye & Ear Hospital), Melbourne, Victoria, Australia
🇦🇺
Lions Eye Institute, Perth, Western Australia, Australia
🇦🇺
Sydney Eye Hospital, Sydney, New South Wales, Australia

PINOT Follow-up Study in End-stage Kidney Disease

Completed

Conditions: Chronic Kidney Disease

Interventions: Procedure: dialysis, kidney transplant

First Posted Date: 2013-01-15

Last Posted Date: 2016-10-26

Lead Sponsor: University of Sydney

Target Recruit Count: 721

Registration Number: NCT01768624

Locations: 🇦🇺
University of Sydney, Sydney, New South Wales, Australia
🇬🇧
University of Oxford, Headington, Oxfordshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy